Feature Channels: Blood

Filters close
Released: 24-Jan-2022 3:40 PM EST
The Latest Research News from the Health Disparities Channel
Newswise

The latest research news from the Health Disparities Channel.

Released: 20-Jan-2022 5:50 PM EST
TV watching linked with potentially fatal blood clots
European Society of Cardiology

Take breaks when binge-watching TV to avoid blood clots, say scientists. The warning comes as a study reports that watching TV for four hours a day or more is associated with a 35% higher risk of blood clots compared with less than 2.5 hours. The research is published today in the European Journal of Preventive Cardiology, a journal of the ESC.1

Released: 20-Jan-2022 5:30 PM EST
‘Superpower’ nano bubbles could treat, prevent current and future strains of SARS-CoV-2
Northwestern University

Scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients and discovered these nano-sized particles can block infection from broad strains of SARS-CoV-2 virus in preclinical studies.

Newswise: American College of Surgeons STOP THE BLEED® program signs with North American Rescue to offer STOP THE BLEED® items
Released: 20-Jan-2022 10:05 AM EST
American College of Surgeons STOP THE BLEED® program signs with North American Rescue to offer STOP THE BLEED® items
American College of Surgeons (ACS)

The American College of Surgeons (ACS) STOP THE BLEED® program recently announced it has signed with a new vendor, North American Rescue®, LLC (NAR), to offer STOP THE BLEED® Kits, equipment, and other bleeding control materials to the public through its online shop.

Newswise: Nano-sized vesicles with ACE2 receptor could prevent, treat infection from current and future strains of SARS-CoV-2
19-Jan-2022 3:15 PM EST
Nano-sized vesicles with ACE2 receptor could prevent, treat infection from current and future strains of SARS-CoV-2
University of Texas MD Anderson Cancer Center

Researchers from MD Anderson and Northwestern University have identified natural extracellular vesicles containing the ACE2 protein in the blood of COVID-19 patients that act as decoys to block infection from SARS-CoV-2

Newswise:Video Embedded automating-blood-smears-for-easier-malaria-diagnosis
VIDEO
12-Jan-2022 1:15 PM EST
Automating Blood Smears for Easier Malaria Diagnosis
American Institute of Physics (AIP)

In Review of Scientific Instruments, researchers have developed devices to automate blood smears. Their devices, called autohaem smear and smear+, can consistently create high-quality smears equivalent to those created by human experts, automating the smearing process so every smear is correct and consistent. A key goal of the project was to make the devices accessible to as many people as possible, so the researchers designed their devices to be easy to build, using readily available or 3D-printed components.

   
17-Jan-2022 3:05 PM EST
Direct oral anticoagulants significantly decrease recurrent venous thrombosis for adult cancer patients, Mayo Clinic study finds
Mayo Clinic

Direct oral anticoagulants should be considered the standard of care to treat adult patients with cancer-associated thrombosis, according to a new, ongoing study by Mayo Clinic researchers.

Newswise: Blood & Marrow Transplant Outcomes Exceed Expectations
Released: 17-Jan-2022 10:05 AM EST
Blood & Marrow Transplant Outcomes Exceed Expectations
Cedars-Sinai

The Cedars-Sinai Cancer Blood & Marrow Transplant Program’s one-year patient survival rate exceeded expectations compared to transplant centers in the U.S. whose similar patients underwent allogeneic transplants, according to a national report that tracks those outcomes.

Newswise:Video Embedded bare-shelves-in-the-blood-bank-means-threat-to-patient-care
VIDEO
Released: 14-Jan-2022 4:25 PM EST
Bare shelves in the blood bank means threat to patient care
Michigan Medicine - University of Michigan

A critical shortage of blood, which has stretched supplies thin nationwide, threatens hospitals' ability to provide many types of patient care. The Red Cross has just declared the first-ever national blood crisis. A blood bank director with nearly 40 years of experience urges every eligible person to step up and make an appointment to donate as soon as possible.

Newswise: The Medical Minute: Yes, the hospital needs your blood. And yes, it’s safe to give.
Released: 13-Jan-2022 7:05 AM EST
The Medical Minute: Yes, the hospital needs your blood. And yes, it’s safe to give.
Penn State Health

What does a blood shortage mean for patients? How did we get here? And why Type O? A Penn State Health blood bank director weighs in.

12-Jan-2022 11:05 AM EST
New blood cancer gene defect can be treated with existing drugs
Queen's University Belfast

A defective gene, normally found in blood cancers, could be treated with drugs already available for cancers with similar gene defects, scientists at Queen’s University Belfast and the University of Birmingham have revealed.

Newswise: New Research in JNCCN Raises Awareness of the Dangers of Septic Shock in Blood Cancer Patients
Released: 12-Jan-2022 8:35 AM EST
New Research in JNCCN Raises Awareness of the Dangers of Septic Shock in Blood Cancer Patients
National Comprehensive Cancer Network® (NCCN®)

New research in the January 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined the impact of septic shock on people with hematologic malignancies, finding 67.8% died in fewer than 28 days and only 19.4% remained alive after 90 days.

Newswise: Researchers at Children’s Hospital Los Angeles are unraveling the biological mechanism that triggers pain in people with sickle cell disease—and confirming what mothers have been saying all along
Released: 10-Jan-2022 10:05 AM EST
Researchers at Children’s Hospital Los Angeles are unraveling the biological mechanism that triggers pain in people with sickle cell disease—and confirming what mothers have been saying all along
Children's Hospital Los Angeles

Over the course of more than three decades studying sickle cell disease and caring for patients, Thomas Coates, MD, has learned an important lesson: listen to the mothers. It is their detailed accounts of their children’s pain that inspired his current research focus.

Released: 6-Jan-2022 12:05 PM EST
Emergency Response, Nervous Toxicity, Liver Injury Markers, and More Featured in January 2022 Toxicological Sciences
Society of Toxicology

The January 2022 issue of Toxicological Sciences launches the New Year with investigations in clinical and translational toxicology, as well as emerging technologies, methods, and models.

   
Released: 4-Jan-2022 10:05 AM EST
Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy
Children's Hospital of Philadelphia

Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia (B-ALL), rendering malignant cells resistant to the effects of CD22-directed immunotherapies, according to a recent study by researchers at Children’s Hospital of Philadelphia (CHOP). The findings could allow oncologists to screen new patients to see if their leukemic cells contain alternatively spliced CD22 mRNA variants, which could reveal which patients might not respond to anti-CD22 therapies and would need alternative treatment plans. The study was published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

Newswise: Computer Model of Blood Enzyme May Lead to New Drugs for Cardiovascular Disease
Released: 3-Jan-2022 4:05 PM EST
Computer Model of Blood Enzyme May Lead to New Drugs for Cardiovascular Disease
UC San Diego Health

Computer simulations from UC San Diego School of Medicine reveal the action mechanism and substrate specificity of an important blood enzyme. These findings open the door for new therapeutics against cardiovascular disease, and further support a unifying theory of phospholipase function.

Newswise: Researchers identify biomarker for depression, antidepressant response
Released: 3-Jan-2022 11:00 AM EST
Researchers identify biomarker for depression, antidepressant response
University of Illinois Chicago

Researchers have identified a biomarker in human platelets that tracks the extent of depression.

Newswise: World Renowned Geneticist and Sickle Cell Disease Expert Takes Helm of Genetic Medicine Department at Johns Hopkins
Released: 28-Dec-2021 9:00 AM EST
World Renowned Geneticist and Sickle Cell Disease Expert Takes Helm of Genetic Medicine Department at Johns Hopkins
Johns Hopkins Medicine

South African geneticist Ambroise Wonkam, M.D., Ph.D., D.Med.Sc., has been selected as Johns Hopkins Medicine’s director of the Department of Genetic Medicine and the McKusick-Nathans Institute of Genetic Medicine.

20-Dec-2021 7:30 AM EST
Study Confirms Nutrient’s Role in Childhood Blood Cancer
NYU Langone Health

A molecular building block of many animal proteins, the amino acid valine, plays a key role in cancerous growth seen in T cell acute lymphoblastic leukemia, a new study shows.

Newswise: Could EKGs Help Doctors Use AI to Detect Pulmonary Embolisms?
Released: 21-Dec-2021 3:10 PM EST
Could EKGs Help Doctors Use AI to Detect Pulmonary Embolisms?
Mount Sinai Health System

Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI) algorithms can detect signs of these clots in electrocardiograms (EKGs), a finding which may one day help doctors with screening.

   
Released: 17-Dec-2021 11:05 AM EST
New gene therapy could provide cure for sickle cell disease, according to UAB study
University of Alabama at Birmingham

Although unproven, this novel sickle cell therapy serves as a potential cure. More measures need to be taken to determine long-term function and organ improvement.

16-Dec-2021 12:00 PM EST
New potential treatment for graft-versus-host-disease and other inflammatory disorders
UC Davis Health (Defunct)

UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease, an inflammatory condition that develops in patients after their allogeneic hematopoietic stem cell transplantation.

Released: 15-Dec-2021 7:00 AM EST
Researchers Explore Potential Causes, Treatments for ‘Long COVID’ Complications
American Physiological Society (APS)

A new review explores the physiology behind and proposed management strategies for body-wide symptoms of the post-acute sequelae of SARS-CoV-2 (PASC), otherwise known as “long COVID.” The review is published ahead of print in the American Journal of Physiology-Cell Physiology.

Released: 14-Dec-2021 9:35 AM EST
For children, young adults with recurrent AML, immunotherapy shows promise
Washington University in St. Louis

Researchers at Washington University School of Medicine in St. Louis have shown, in a small clinical trial, that an immunotherapy harnessing pre-activated natural killer cells can help some children and young adults with recurrent AML and few other treatment options.

9-Dec-2021 10:55 AM EST
New Drug Combo May Improve Family-donated Stem Cells as Blood Cancer Treatment
NYU Langone Health

A drug combination can safely prevent transplanted stem cells (graft) from attacking the recipient’s (host) body, allowing them to develop into healthy new blood and immune cells, a new study shows.

Newswise: Yale Study Reveals Clues to Help Treat Patients With COVID-19 Related Blood Clots
13-Dec-2021 3:55 PM EST
Yale Study Reveals Clues to Help Treat Patients With COVID-19 Related Blood Clots
Yale Cancer Center/Smilow Cancer Hospital

Blood clots or thromboembolic complications in patients with COVID-19 are associated with increased levels of various proteins that cause blood to clot, compared with people with blood clots unrelated to COVID-19, according to a small study by Yale Cancer Center researchers. These findings may offer insights into novel therapeutic strategies to treat patients with COVID-19 related blood clots. The findings were reported today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.

Newswise: Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-Cell Lymphoma
Released: 13-Dec-2021 3:55 PM EST
Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-Cell Lymphoma
Yale Cancer Center/Smilow Cancer Hospital

The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being presented today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.

10-Dec-2021 5:15 PM EST
Venetoclax combination therapies found effective against challenging subtypes of acute myeloid leukemia
University of Texas MD Anderson Cancer Center

Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory AML with a specific mutation, high-risk AML and treated secondary AML. Researchers from The University of Texas MD Anderson Cancer Center presented numerous studies involving venetoclax combination therapy for AML at the 2021 American Society of Hematology (ASH) Annual Meeting.

Released: 13-Dec-2021 2:40 PM EST
The American Society of Hematology recognizes Stephen Ansell, M.D. of Mayo Clinic with the 2021 Ernest Beutler Lecture and Prize
Mayo Clinic

The American Society of Hematology (ASH) has recognized Stephen Ansell, M.D., of Mayo Clinic with the highly distinguished Ernest Beutler Lecture and Prize as part of its Honorific Awards to recognize exemplary hematologists who have made significant contributions to the field and have been nominated by ASH members.

Newswise: Drug combination found to keep chronic lymphocytic leukemia in young patients in remission for several years
9-Dec-2021 10:00 AM EST
Drug combination found to keep chronic lymphocytic leukemia in young patients in remission for several years
Dana-Farber Cancer Institute

Young patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the cancer in remission. A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions of the disease.

Newswise: Examining the Development of T-cell Acute Lymphoblastic Leukemia
10-Dec-2021 12:05 PM EST
Examining the Development of T-cell Acute Lymphoblastic Leukemia
Rutgers Cancer Institute

Researchers from Rutgers Cancer Institute of New Jersey, the state’s only NCI-designated Comprehensive Cancer Center, examined the effects of SIRT1, an enzyme located primarily in the cell nucleus that contributes to cellular regulation on the transformation of T-cells.

Newswise: For patients with multiple myeloma, vaccination offers protection from COVID-19, but less than other cancer patients receive
11-Dec-2021 3:05 PM EST
For patients with multiple myeloma, vaccination offers protection from COVID-19, but less than other cancer patients receive
Dana-Farber Cancer Institute

For patients with the blood cancer multiple myeloma, vaccination against COVID-19 provides some protection against coronavirus infection but to a far lower degree than the general population of cancer survivors, a new study by Dana-Farber Cancer Institute investigators shows.

Released: 11-Dec-2021 4:05 PM EST
Roswell Park Hematologists Present New Research on FLT3 Inhibitors, CART-19 at ASH Annual Meeting
Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center hematology experts in leukemia, lymphoma and other specialties will present new research at the 63rd annual meeting of the American Society of Hematology (ASH), which begins today in Atlanta, Georgia. The many research projects to be highlighted include breakthrough research on CAR T cell therapy, immunotherapy, leukemia, lymphoma and the management of genetic mutations in aggressive and rare blood cancers.

10-Dec-2021 5:20 PM EST
Mount Sinai Researchers Present Encouraging Clinical Trial Results on Novel Therapy for Bone Marrow Cancer
Mount Sinai Health System

Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phase 1b clinical trial. They shared their findings during an oral presentation at the American Society of Hematology annual meeting in December.

Newswise: New study reveals elevated rates of blood cancer precursor condition in groups at high risk for multiple myeloma
11-Dec-2021 5:00 AM EST
New study reveals elevated rates of blood cancer precursor condition in groups at high risk for multiple myeloma
Dana-Farber Cancer Institute

The first results from the largest screening study yet conducted in the U.S. of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.

Newswise: Moffitt Study Shows Lymphoma Patients Can Benefit from Receiving CAR T Sooner
Released: 11-Dec-2021 8:30 AM EST
Moffitt Study Shows Lymphoma Patients Can Benefit from Receiving CAR T Sooner
Moffitt Cancer Center

Chimeric antigen receptor T-cell therapy or CAR T is a breakthrough treatment for patients with certain types of blood cancers. The cellular therapy uses a patient’s own immune cells that are reengineered to better seek out and destroy cancer cells. The single infusion treatment is approved for patients who have relapsed after two or more types of therapy but results from the ZUMA-7 clinical trial show lymphoma patients can benefit from receiving the CAR T product axicabtagene ciloleucel (Yescarta) sooner.

9-Dec-2021 4:50 PM EST
Axi-cel CAR T cell therapy shows enhanced responses and continued benefit for high-risk lymphoma patients
University of Texas MD Anderson Cancer Center

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy. These results were reported at the 2021 American Society of Hematology (ASH) Annual Meeting.

7-Dec-2021 4:20 PM EST
Potentially Serious Side Effect Seen in Patient after Immunotherapy
Mount Sinai Health System

Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma. Their findings were published as a case study in Nature Medicine in December.

Newswise: Exploring New Cancer Therapies that use a Patient’s Immune System to Fight Tumors
Released: 9-Dec-2021 11:40 AM EST
Exploring New Cancer Therapies that use a Patient’s Immune System to Fight Tumors
Rutgers Cancer Institute

Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients.

Newswise: John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual Conference
Released: 9-Dec-2021 8:05 AM EST
John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual Conference
Hackensack Meridian Health

Researchers from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a part of the Georgetown Lombardi Comprehensive Cancer Center, will present updates on treatment advances in multiple myeloma, lymphoma, leukemia, and bone marrow transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually and live at the Georgia World Congress Center in Atlanta from December 11-14, 2021.

Released: 7-Dec-2021 12:05 PM EST
Targeted nanomedicine reduces vascular lesions, could help prevent stenosis
University of Chicago

A new targeted nanomedicine treatment developed at the University of Chicago has shown promise in reducing vascular lesions caused by atherosclerosis in a mouse model.

Released: 6-Dec-2021 1:30 PM EST
New marker for better assessing the severity of Covid-19
Ludwig Maximilians Universität München (Munich)

Biomedical scientists at LMU have found a new marker in the blood of Covid-19 patients. It furnishes insights into the course and development of the disease and could lead to better diagnoses.

Newswise: HPV-associated Head and Neck Cancer Blood Test Shows Promise as a Test to Replace Tissue Biopsy
1-Dec-2021 11:40 AM EST
HPV-associated Head and Neck Cancer Blood Test Shows Promise as a Test to Replace Tissue Biopsy
Massachusetts Eye and Ear

New research shows liquid biopsy for HPV-associated head and neck cancer is more than 98% accurate and obtained a diagnosis 26 days quicker on average than conventional tissue biopsy, in addition to costing 38% less. With HPV-associated head and neck cancer rates on the rise, there is a great need for more accurate, less-invasive, faster and less expensive diagnostic tests.

Released: 1-Dec-2021 11:55 AM EST
Seattle Children’s Presents Pediatric Cancer Immunotherapy Research Findings at American Society of Hematology Annual Meeting 2021
Seattle Children's Hospital

Seattle Children’s today announced five oral presentations at the American Society of Hematology (ASH) annual meeting, the world’s premier event in malignant and non-malignant hematology set to take place from Dec. 11-14.

Newswise: Blood Bubbles Reveal Oxygen Levels #ASA181
16-Nov-2021 2:45 PM EST
Blood Bubbles Reveal Oxygen Levels #ASA181
Acoustical Society of America (ASA)

Researchers have developed microbubbles to acoustically detect blood oxygen levels, since the microbubble shells are altered by structural hemoglobin changes in response to oxygen. The gas filling of the microbubbles causes them to oscillate and vibrate when ultrasound is applied, scattering energy and generating an acoustic response that can be detected by a clinical ultrasound scanner. Preliminary results show a strong correlation between oxygen concentration and the acoustic bubble response.

   
24-Nov-2021 12:45 PM EST
COVID-19: Measuring viral RNA to predict which patients will die
Universite de Montreal

A statistical model developed by Université de Montréal researchers uses a blood biomarker of SARS-CoV-2 to identify infected patients who are most at risk of dying of COVID-19.

Released: 24-Nov-2021 2:35 PM EST
State Stem Cell Agency Awards $4M for Blood Cancer Immunotherapy at UC San Diego
UC San Diego Health

The California Institute for Regenerative Medicine (CIRM) approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

Newswise: Clonal Hematopoiesis in Donor May Improve Bone Marrow Transplant Outcome
Released: 22-Nov-2021 8:00 AM EST
Clonal Hematopoiesis in Donor May Improve Bone Marrow Transplant Outcome
Johns Hopkins Medicine

Clonal hematopoiesis, a condition in which mutations associated with blood cancers are found in the blood of healthy people, is common with aging. When looking for appropriate stem cell/bone marrow donors, clinicians tend to stay away from older donors with clonal hematopoiesis (CH) because of concerns about passing potentially premalignant stem cells to the recipient.

Newswise: Jeffrey L. Carson, MD, Recognized for Global Impact on Improving Transfusion Medicine
Released: 18-Nov-2021 11:45 AM EST
Jeffrey L. Carson, MD, Recognized for Global Impact on Improving Transfusion Medicine
Rutgers Robert Wood Johnson Medical School

Jeffrey L. Carson, MD, whose research has profoundly reshaped transfusion medicine is being honored by the American College of Physicians (ACP) with the John Phillips Memorial Award for Outstanding Work in Clinical Medicine for his career-long journey to improve health outcomes for patients.



close
2.65655